TD Bank Plans New C$10 Billion Share Buyback
TD Bank plans to repurchase up to C$10 billion of common shares after completing a C$7 billion buyback, subject to regulatory approval.
TD Bank Plans New C$10 Billion Share Buyback
TD Bank plans to repurchase up to C$10 billion of common shares after completing a C$7 billion buyback, subject to regulatory approval.
Treasury Sanctions 10 Over Tren de Aragua ATM Scheme
The U.S. Treasury sanctioned 10 targets tied to a Tren de Aragua network accused of using ATM jackpotting to steal millions from U.S. banks.
Fed’s Barr Says Policy Adjustment Needed to Reach 2% Inflation Target
Fed Governor Michael Barr said inflation is not trending to 2% in a timely way and that further policy adjustments may be needed.
TC Energy Advances Coastal GasLink Phase 2 After LNG Canada FID
TC Energy said Coastal GasLink Phase 2 will proceed after LNG Canada approved its expansion, nearly doubling pipeline capacity with construction expected in 2027.
MMA.INC Raises Annualized Cost Cuts Above $2.51 Million
MMA.INC said annualized cash operating cost reductions exceeded $2.51 million after more than $800,000 of additional cuts since July.
Immix Biopharma Reports 89% Response Rate in NEXICART-2
Immix Biopharma reported an 89% complete response rate in its 45-patient NEXICART-2 trial and plans a final readout and BLA submission in mid-2027.
BeyondSpring Opens $11.9M ATM Offering as China Deal Advances DUBLIN-4
BeyondSpring launched an ATM offering of up to $11.9 million while transferring its China subsidiary interest and securing support for DUBLIN-4.
Aldeyra to Seek FDA Review of Reproxalap Rejection
Aldeyra plans to seek FDA formal dispute resolution over reproxalap after three complete response letters and expects an FDA meeting in Q4 2026.
Pharming CEO Fabrice Chouraqui Steps Down Immediately
Pharming CEO Fabrice Chouraqui has stepped down immediately, with its CFO and chief commercial officer appointed interim co-CEOs.
AstraZeneca Invests $2 Billion in Summit Therapeutics
AstraZeneca will invest $2 billion in Summit Therapeutics for a roughly 12% stake while collaborating on cancer drug trials.
